Compare McDonald's Corp (MCD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs TG Therapeutics Inc — how do they compare? McDonald's Corp trades at $235.23 (market cap $167.64B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: McDonald's Corp is far larger — about 20.5× TG Therapeutics Inc's market cap, and McDonald's Corp pays a 3.26% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 164 Days and TG Therapeutics Inc for 16 Days on average.
| MCD | TGTX | |
|---|---|---|
Market Cap | $167.64B | $8.16B |
Volume | 11,320,306 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $59.06 |
52-Week Low | $230.88 | $26.94 |
Typical Hold Time | 164 Days | 16 Days |
Enterprise Value | $221.41B | $8.37B |
Dividend Yield | 3.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $236.9, up 2.61% today, but technical indicators signal a bearish trend. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth remains steady, reaching $26.89B in 2025, while net income margin stands at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and improved customer experience to drive growth amid competitive pressures.
The outlook for MCD is mixed: analyst consensus is bullish with a $284.70 price target, but technical weakness and inflation risks pose challenges. Investment appeal lies in its robust profitability and dividend payments, though high debt levels and margin pressures from rising costs require monitoring for sustained shareholder value.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
